Advertisement

Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity

Antonia Cagnetta, Michele Cea, Teresa Calimeri, Chirag Acharya, Mariateresa Fulciniti, Yu-Tzu Tai, Teru Hideshima, Dharminder Chauhan, Mike Y. Zhong, Franco Patrone, Alessio Nencioni, Marco Gobbi, Paul Richardson, Nikhil Munshi and Kenneth C. Anderson

Article Information

Citation 
vol. 122 no. 7 1243-1255
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted February 7, 2013
  • Accepted June 8, 2013
  • Published online August 15, 2013.

Article Versions


Contributors 
  • Antonia Cagnetta, 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and 2Department of Hematology and Oncology, and
  • Michele Cea, 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and 2Department of Hematology and Oncology, and
  • Teresa Calimeri, 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and
  • Chirag Acharya, 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and
  • Mariateresa Fulciniti, 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and
  • Yu-Tzu Tai, 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and
  • Teru Hideshima, 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and
  • Dharminder Chauhan, 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and
  • Mike Y. Zhong, 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and
  • Franco Patrone, 3Departments of Internal Medicine, Istituto Di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria San Martino-IST, Genova, Italy
  • Alessio Nencioni, 3Departments of Internal Medicine, Istituto Di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria San Martino-IST, Genova, Italy
  • Marco Gobbi, 2Department of Hematology and Oncology, and
  • Paul Richardson, 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and
  • Nikhil Munshi, 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and
  • Kenneth C. Anderson, 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output